The work of physician-scientist Matthias H. Tschöp, MD, has transformed the fight against obesity and diabetes. As the Banting Medal for Scientific Achievement honoree, he shared insights into the ongoing quest to reverse obesity, including the possibilities offered by the approval of tirzepatide for the treatment of type 2 diabetes.

Studies harness real-world data for vital insights into patient populations and can help determine the delivery of care for patients with diabetes. Experts, including Kristi Reynolds, PhD, MPH, FAHA, FACE, discussed the utility of real-world data and how having access to electronic health records can help in examining long-term trends.

Guidelines and standards of care are helpful for many, but some populations require a more individualized approach to diabetes care. Experts, including Rodolfo J. Galindo, MD, shared the tools they’ve made available to patients who may need alternative ways to monitor and self-manage their diabetes.

Data continue to provide strong evidence favoring metabolic surgery to other treatment options for type 2 diabetes remission. Principal Investigator John Kirwan, MSc, PhD, will present ARMMS-T2D study results comparing surgery versus medical and lifestyle intervention in patients with the disease, as well as long-term effects post-surgery.

Experts in diabetes and eye health will discuss how the therapies used in the treatment of diabetes relate to the development and progression of diabetic retinopathy. Risa Wolf, MD, will share data that suggests GLP-1 receptor agonists can worsen diabetic retinopathy.

The COORDINATE-Diabetes trial studied the effects of prescribing three recommended classes of drugs to patients with both type 2 diabetes and atherosclerotic disease compared to standard care. Investigators including Neha Pagidipati, MD, MPH, will review the results in a Scientific Sessions symposium.

Phase 2 trial results suggest retatrutide may offer a triple therapy option to address the multiple metabolic factors that affect people who are obese, regardless of type 2 diabetes status, said Arun J. Sanyal, MD. He and other investigators will share new data on this GIP/GLP-1/glucagon receptor triagonist and its effects on obesity, type 2…

Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists are making an impact in treating patients with type 2 diabetes who may be at high risk for atherosclerotic cardiovascular disease and heart failure. Darren K. McGuire, MD, MHSc, will review both classes of drugs as part of an expert panel.

As treatments for diabetic kidney disease evolve, a panel of diabetes care experts will discuss what is happening in the world of antihyperglycemic and antihypertensive agents—and beyond—as the disease continues to be a prevalent complication from diabetes. Christine Limonte, MD, will discuss whether diabetes care professionals are following guidelines in using new therapies.

Michael Sefton, ScD, and a collaborative panel of experts will discuss cell therapy and strategies for delivering it to patients with type 1 diabetes. Topics will include identifying sites for the therapy, protecting the immune cells, and, once the cells are transplanted, monitoring the patient.